Hemoducto Venoso: Cambio en el Paradigma de Tratamiento


Augusto Pichard
2014-08-07

Director Innovation and Structural Heart Disease,  Vice Chair, Medstar Heart Institute, 
Medstar Washington Hospital Center. Professor of Medicine (Cardiology),
Georgetown University Medical School.

More articles by this author

Prevención y Manejo de dificultades en la via radial

Pablo Vázquez Grenno 2014-08-07Sanatorio Americano. CCAMontevideo. Uruguay

Caso Clinico

Alfaro Marchena Noriega2014-08-07Vicepresidente Sociedad Panameña de CardiologíaPresidente Fundación Cardiológica de Panamá

Chronic Total Occlusions

Luis A Guzman2014-08-07Director, Cardiovascular InterventionsUniversity of Florida-Jacksonville

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...